Researchers at a public health institute in Suwon, south of Seoul, examine materials collected from a Chinese woman to find the cause of her mysterious pneumonia symptoms on January 9, 2020.
Gilead's experimental drug has not been approved for use by any drug regulator in the world, the company said in a statement.
Research biopharmaceutical company Gilead Sciences announced last week that it has joined efforts to contain the 2019 novel coronavirus (2019-nCoV) through requested release of an experimental drug known as remdesivir.
A research institute in China's virus-hit Wuhan city has applied for a patent on the use of a drug made in the USA after it was found to be effective in treating patients infected with the coronavirus, raising questions whether the lab's move violated the intellectual property rights.
China is getting ahead in the search for treatments of coronavirus that has killed over 600 people infected more than 28,000 in the outbreak, the virus has been spread to more than 20 countries. The patent would leverage negotiations for access to the drug, along with pricing benefits.
However, Gilead Sciences Inc which developed Remdisivir said that the drug is not yet licensed or approved anywhere globally and it has not been demonstrated to be safe or effective for coronavirus infection treatment. The two drugs' efficacies on humans required further clinical tests, the institute said in the statement.
These were the details of the news China lab seeks patent on use of Gilead's coronavirus treatment for this day.
In the meantime, the Wuhan Institute of Virology has applied for a patent in China to use remdesivir to treat the coronavirus, according to a statement on the institute's website.
As the Associated Press reports, this all comes back to the trade war with China, and the country's practice of "abus [ing] its regulatory system to pressure foreign companies to hand over valuable technology".
For their part, the Chinese authorities have acknowledged that there may be "intellectual property barriers", but they said the patent application had been made in order to "protect national interests".
It has already been used on the first USA coronavirus patient in Washington state, who improved after getting the drug, as well as a handful of other coronavirus patients in the West. However, it said it would temporarily drop its patent claims if the opportunity arose to collaborate with foreign pharmaceutical firms to fight the epidemic. The company also highlighted limited clinical data that is available from the emergency use of the drug candidate in treating patients with Ebola virus infection. The patent filing will need to prove that the drug works on this coronavirus strain, 2019-nCoV, in a way that's different from its effect on other viruses in the same category. The man has been released from the hospital and is recovering at home, but it's not clear whether the Gilead drug helped him or not.
Trump fumbles tweet congratulating Super Bowl champs the Chiefs
Two people were taken into custody and the Kansas City Police Department said the driver is "under investigation for impairment". The victory rally will start just after the parade concludes and the team will take the stage in front of Union Station.